Letter to the Editor

Proton-pump-inhibitor-induced Hepatitis

Authors: Kamran Darabi, MD

Abstract

A 39-year-old woman presented to the hospital with upper abdominal pain, vomiting, and malaise for two days. Two weeks before admission her primary physician prescribed pantoprazole for gastroesophageal reflux symptoms. She denied the intake of other medications or herbal products. Her past medical history was remarkable for anemia secondary to heavy menses. She had pica for ice for many years and was transfused several years ago for a low hemoglobin level. Clinical examination and laboratory tests suggested a diagnosis of hepatitis. Test results were as follows: prothrombin time 16.6 seconds, international normalized ratio 2.1, total bilirubin 1.2 mg/dL, direct bilirubin 0.4 mg/dL, alkaline phosphatase 89, aspartate aminotransferase (serum glutamic-oxaloacetic transaminase) 964, alanine aminotransferase (serum glutamic-pyruvic transaminase) 3,061 IU/L, gamma glutamyl transpeptidase 252 IU/L, albumin 3.1 g/dL, total protein 5.9 g/dL, hemoglobin 8.1 mg/dL, and mean corpuscular volume 72. Duplex ultrasound revealed no evidence of hepatosplenomegaly or bile obstruction. Doppler ultrasounds revealed normal flow within the hepatic arteries and veins. Serologies excluded an infectious, metabolic, or autoimmune cause of hepatitis. The patient's condition and laboratory tests gradually improved with symptomatic treatment and the discontinuation of pantoprazole, suggesting proton-pump-inhibitor-induced hepatitis.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Delhotal-Lands B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M. Pharmacokineticsof lansoprazole in patients with renal or liver disease of varying severity. EurJ Clin Pharmacol1993;45:367–371.
 
2. Koury SI, Stone CK, La Charite DD. Omeprazole and the development of acute hepatitis. Eur J Emerg Med 1998 Dec.;5:467–469.
 
3. Romero-Gomez M, Otero MA, Suarez-Garcia E, Garcia-Diaz E, Fobelo MJ, Castro-Fernandez M. Acute hepatitis related to omeprazole. Am J Gastroenterol 1999;94:1119–1120.
 
4. Viana de Miguel C, Alvarez Garcia M, Sanchez Sanchez A, Carvajal Garcia-Pando A. Lansoprazole-induced hepatitis [Article in Spanish]. Med Clin (Barc) 1997;108:599–.
 
5. Cordes A, Vogt W, Maier KP. Pantoprazoleinduced hepatitis [Article in German]. Dtsch Med Wochenschr 2003;128:611–614.
 
6. Lucena MI, Andrade RJ, Romero-Gomez M, Fernandez MC. Lansoprazole-induced hepatic dysfunction. Ann Pharmacother. 2003 Nov; 37:1731.